• PULL recently received Company Code from Canada’s Natural and Non-prescription Health Products Directorate
• Code allows PULL to submit application to sell its first functional mushroom product
• Company intends to submit additional NPN applications during 2021 as part of larger strategy to develop portfolio of functional mushroom wellness products

Functional mushrooms, those that provide a health benefit beyond just nutrition, are growing in popularity worldwide amid an accelerating trend to fend off viruses with immune-boosting food and drinks. Looking to seize part of a global functional mushroom market forecast by Data Bridge Market Research to hit $555.9 billion by 2028, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is checking the boxes to soon commercialize its new line of products.

Pure Extracts, a diversified plant-based extraction company with reach into cannabis, hemp, functional mushrooms and the burgeoning psychedelics sector, recently received a Company Code from Canada’s Natural and Non-prescription Health Products Directorate (“NNHPD”), an important step in moving towards sales. The code allowed the Company to submit an application for a Class 1 Natural Product Number, or NPN for short, for its first functional mushroom product.

Products that receive an 8-digit NPN have been assessed by Health Canada and deemed to be safe, effective and of high quality under the recommended conditions of use. Once approved, the NPN is added to the Licensed Natural Health Products Database where information about the product is available for viewing. The database includes information on a variety of natural health products, such as vitamin supplements, herb and plant-based remedies, probiotics, traditional medicines and more.

Pure Extracts intends to submit additional NPN applications during 2021 as part of its strategy to develop a portfolio of functional mushroom wellness products to sell through Pure Mushrooms Corp., its new, 100%-owned, subsidiary. Pure Mushrooms will employ a direct-to-consumer model, selling its goods through an e-Commerce portal being designed while the licensing process is under way. The new products will be sold under the “Pure Mushrooms” moniker.

Initially, the Company will work with a co-packer to meet consumer demand for Pure Mushrooms products while it explores optimizing existing extraction equipment at its state-of-the-art processing facility outside of Whistler, British Columbia. Planning ahead, Pure Extracts, which holds a Standard Processing License from Health Canada allowing it to manufacture cannabis goods, had its purpose-built facility constructed to meet Good Manufacturing Practices standards of the European Union, aligning for future global distribution of products and formulations were allowed by law.

Pure Extracts CEO Ben Nikolaevsky commented that his team is excited about the milestones ahead to enter the functional mushroom wellness sector that is experiencing “tremendous growth and consumer awareness.” He added that the company expects sales of the new products to begin by the end of this quarter.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Imagin Medical Inc. announced that it has now raised $2.165 million of the recent its convertible note offering
• The closing of the latest funding tranche will support the company’s progress toward the commercialization of its revolutionary bladder cancer visualization technology once final FDA approval is granted
• With better viewing options, the technology is designed to make it easier for surgeons to detect the full parameters of bladder tumors and remove them more completely
• Bladder cancer is one of the most prevalent cancers in the United States, particularly in men
• The technological improvement of these surgical procedures can provide an attractive cost benefit outcome and improved peace of mind as the potential need for repeated tumor-resecting procedures is reduced

As Imagin Medical (CSE: IME) (OTCQB: IMEXF) announces the closing of the second tranche of a convertible note offering to investors, the company continues building momentum toward the anticipated commercialization of its revolutionary cancer visualization technology. Imagin’s proprietary i/Blue Imaging (TM) System is a means of improving cystoscopies through the simultaneous use of white and blue imaging protocols that allow surgeons to detect and resect bladder tumors with greater accuracy and ease than has been possible before. The second tranche closing, announced Feb. 18 (https://ibn.fm/8gVHc), brings the amount raised for Imagin’s convertible note up to $2.165 million. Principal of notes that will accrue 10 percent interest annually and mature 18 months after the date of issue unless they are repurchased, redeemed or converted before that time. Imagin is aiming to commercialize its i/Blue Imaging (TM) System once final U.S. Food and Drug Administration (“FDA”) approval has been granted, and then apply its experience with the system toward the manufacture and commercialization of similar technology for use in other types of surgical procedures, i.e. laparoscopic. The I/Blue System uses blue light with a contrast agent, Cysview(TM) that causes the tumor to fluoresce  agent and deliver real-time images of the bladder for resection. While the existing blue light system has required surgeons to switch back and forth between white and blue light images, Imagin’s IP simplifies the process and makes it more effective by showing the white and blue light images side-by-side on the same monitor, utilizing hardware that is compatible with almost any endoscope already in use by hospitals and surgical centers so that they don’t have to acquire entirely new systems. The company estimates that approximately 95 percent of today’s cystoscopies continue to be performed with white light simply because of the hardware costs and challenges of acquiring blue light capability. Photocure reported to the 21st Annual Meeting of the Society of Urologic Oncology in December that its latest investigation found Cysview didn’t significantly affect the cost of cystoscopies and helped surgeons find tumor recurrences that would otherwise have been missed (https://ibn.fm/t9SLP). A report by Urology Times found that the use of blue light cystoscopy (“BLC”) under the trade name Cysview in tandem with white light during initial transurethral resection of bladder tumors (“TURB”) “lowered costs by $4,660 over 5 years compared with use of white light cystoscopy alone” and led to a lower overall burden for patients (https://ibn.fm/Cz8GX). For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• PowerTap Hydrogen Fueling has signed a definitive agreement with the Andretti Group to create an optimized network by leveraging the latter’s operational expertise and global reach
• PowerTap plans to have 500 operational hydrogen filling stations deployed across the country by the end of 2025
• The existing business model’s deployment of hydrogen stations expedites rollout due to the existing fuel operations on each site
• The hydrogen fuel cell vehicle market worldwide was valued at $651.9 million in 2018 and is expected to grow to over $42 billion by 2026

Stemming from the announcement made by Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) on January 26, 2021, about the Definitive Agreement between investee PowerTap Hydrogen Fueling and the Andretti Group for the production and deployment of hydrogen fuel units across California, more details have been released regarding the agreed-on business model, as well as the agreement’s benefits for the parties involved (https://ibn.fm/WYoYt).

PowerTap is working to build and expand its hydrogen fueling station network, initially across North America, starting the second half of 2021. The platform is believed to be more cost-effective and expandable than other hydrogen filling station’s models. The significant advantage over these companies comes from PowerTap’s smaller physical footprint and capacity to produce hydrogen on-site. Other companies purchase hydrogen at high prices and store it.

To be eligible to host a hydrogen fueling station, a site needs to meet a series of requirements, including: to have an existing fuels retailer, a usable area of at least 1000 square feet, as well as access to utilities, including natural gas, electricity, and water.

The key points for the business model are:

• The retailer provides the land, with no leasing expenses required of PowerTap
• PowerTap, at their own expense, will install and maintain the modular hydrogen production and dispensing unit. These expenses also include branding costs and utilities.
• The retailer will market hydrogen fuel and generate profit the same way traditional fuel sales are conducted.

Under the agreement, participating retails have a number of advantages, including:

• A high-yield opportunity to create revenue out of the land that is not being used to full potential
• Retailers are eligible to receive a portion of the carbon credit revenue
• Minimal operating costs and high earnings as an additional means of profit
• New clientele group, generating additional purchases of other products or services
• The on-site production allows a competitive price (go-to-market) versus the delivered supply price

The advantages for PowerTap include:

• No land purchase or leasing expenses
• Co-development that provides access to prime and higher trafficked real estate
• A faster entitlement process due to the existing fuel operation
• Ability to leverage the Andretti Group’s established operations expertise and geographical reach for a more optimized network
• Ability to expedite rollout, with the deployment of over 500 PowerTap modular hydrogen production and dispensing units by the end of 2025

The PowerTap technology has already been deployed across multiple hydrogen fueling stations in both public and private enterprises. These can be found in California, Maryland, Massachusetts, and Texas. By the end of 2025, PowerTap plans to deploy over 500 stations at existing truck stops and gas stations across the country. At present, there are under 100 active hydrogen fueling stations operational and available to consumers.

The hydrogen fueling network plan enables PowerTap and by extension Clean Power Capital to access a fast-growing market rife with expansion opportunities. According to Allied Market Research, the global hydrogen fuel cell vehicle market, valued at $651.9 million in 2018, is expected to grow at a CAGR of 66.9% to 2026, reaching an estimated value of $42,038.9 million (https://ibn.fm/Rg9Te). The key factor influencing the push for hydrogen fuel vehicles is the surge in environmental concerns over traditional fossil fuels. Hydrogen fuel does not generate greenhouse gas (“GHG”) emissions during operation like diesel and gasoline-powered vehicles.

The United States is already engaging in the hydrogen economy and currently leads in the number of hydrogen cell vehicles globally. The government is investing hundreds of millions of dollars per year in the hydrogen fuel industry, helping potentially create approximately 3.4 million jobs within the next three decades (https://ibn.fm/qF0M4).

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19
• Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disorders
• VTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray with potential to go beyond the current standard of care for acute treatment of social anxiety disorder and other anxiety-related disorders

Anxiety induced by the COVID-19 pandemic during the last year has been linked with surging use of benzodiazepines or “benzos,” a drug class commonly prescribed to treat anxiety and other disorders – a trend with potential to create a new wave of misuse, overuse and addiction among users while leaving physicians concerned about long-term detrimental side effects (https://ibn.fm/FFhjW). As a proactive response to what many critics are calling a “benzo epidemic” (https://ibn.fm/777mk), VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company headquartered in South San Francisco, is currently committed to developing a new generation of medicines that go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders. VistaGen’s CNS pipeline includes multiple innovative drug candidates for treatment of anxiety and depression disorders, each of which has demonstrated favorable safety results in all clinical studies to date and significant commercialization potential in multiple neuropsychiatric markets. Anxiety is on the rise, according to a recent poll by the American Psychiatric Association, revealing that up to 62% of respondents have serious concerns about the effects of COVID-19 on themselves or loved ones. Additionally, prescriptions for benzodiazepines spiked 34% during the early stages of the pandemic according to a study of over three million people, suggesting a link between the rise of anxiety and increased coverage of the COVID-19 issue in the media. The use of benzodiazepines to treat anxiety has grown steadily since their discovery in the 1950s. Commonly classified as “minor tranquilizers,” benzodiazepines are prescribed to treat anxiety, panic disorders and seizures by calming nerve impulses and creating a sense of relaxation and well-being. Unfortunately, however fast-acting and highly effective they may be, benzodiazepines are also extremely addictive, earning them a Schedule IV controlled substance classification by the Drug Enforcement Agency (“DEA”) due to their potential for abuse. In September 2020, the FDA’s Drug Safety Communication (“DSC”) noted that there were 92 million prescriptions of benzodiazepines in 2019 and also detailed safety concerns regarding the serious risks of abuse, addiction, physical dependence, and withdrawal reactions linked to long-term use of benzodiazepines. As a result, in the DSC, the FDA announced that it is requiring an updated Boxed Warning, the FDA’s most prominent type of safety warning, for all benzodiazepine medications (https://ibn.fm/08UKT). According to many medical practitioners, benzodiazepines have serious long-term consequences. Use of the drug has been associated with the development of an increased tolerance that requires higher amounts to achieve the same effect. Additional long-term consequences include addiction, future cognitive problems and incapacitating withdrawal symptoms. VistaGen is committed to developing therapies that go beyond the limits of the current standard of care. To advance on that goal, VistaGen is currently preparing to launch Phase 3 clinical development of its PH94B for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), the third most common mental illness among Americans.  PH94B is a first in class pherine nasal spray designed with potential to deliver the rapid-onset anti-anxiety effects of benzodiazepines, but without the side effects and safety concerns associated with their use.  VistaGen currently anticipates launching its U.S. Phase 3 development program for acute treatment of SAD during the second quarter of this year.  The Company is also planning to launch exploratory Phase 2 studies in 2021 focused on several additional anxiety-related disorders, including adjustment disorder, postpartum anxiety, and pre-procedural (pre-MRI) anxiety (https://ibn.fm/bVbBy). For more information, visit the company’s website at www.VistaGen.com. NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• The FireFly ESV is a highway-legal, application specific, essential services vehicle that is also all-electric with zero emissions
• The vehicle uses the safest lithium-ion battery technology with an expected lifespan of 10 years and a longer operating time per charge
• The 2021 FireFly ESV promises to be the best equipped ESV model yet

Boston-based ev Transportation Services (“evTS”), a specialty vehicle manufacturer providing all-electric lightweight commercial utility vehicles and fleet management solutions, is changing how essential services management and urban e-mobility markets are handled via its highly versatile flagship product, the Firefly ESV (essential services vehicle).

To promote the FireFly ESV, ev Transportation Services announced in January 2021 that legendary golfing pro Ernie Els of South Africa would be serving as the FireFly Global Brand Ambassador (https://ibn.fm/mix0o).

Els is a former number one golfer with 72 professional career victories, including four Major Championships and two World Golf Championships, is also well known for his groundbreaking charitable work and fundraising efforts. Under a multi-year contract, evTS will utilize the golf star’s name, endorsement, and likeness in connection with the advertisement, promotion, and sales of evTS vehicles.

A highway-legal, three-wheeled commercial utility vehicle designed with performance and versatility in mind, the FireFly can be equipped with a number of application specific accessory options, such as License Plate Recognition systems and traffic safety features like directional emergency light bars. The vehicle’s modular bed comes in many purpose-built variants configured to meet the customer’s specialized use requirements, including features such as:

• Basic flatbed
• Electronic lift dump
• Lockable storage with ladder racks
• Insulated food delivery
• Mission specific EMS inserts
• Van (package delivery) box
• Refuse collection tipper
• And many other requested configurations

As an all-electric vehicle, the FireFly ESV uses the safest lithium-ion battery technology currently available (LiFePO₄, Lithium Iron Phosphate). This chemistry provides superior acceleration, a lighter weight design, improved energy-efficiency, and is highly reliable. A proprietary battery management system maintains and monitors the battery, ensuring optimal performance, charging, and range, with an expected lifespan of up to 10 years.

Unlike other vehicles that have been manufactured in the same class, the FireFly’s 102 Volt, 63 HP rated power train, makes it 15% more powerful than the current competition. The Integrated Drive System(TM) features a variable-rate electronic drive technology that optimizes speed and range – up to 100 miles or more per charge, travelling at electronically governed speeds exceeding 50 mph.

With technology like the evTS Data Acquisition System (“eDAS”), and the evTSCONNECT vehicle management portal, fleet operators can collect various performance data and statistical information about their FireFly ESV fleet. They can also track the vehicle’s movement through GPS monitoring and monitor the state of the battery charge.

evTS Chairman and CEO David Solomont said, “It is an honor to be associated with a gentleman who is respected not only in South Africa but throughout the world for his competitive spirit, genuine personality, and extensive philanthropic work.” Els voiced appreciation for evTS’ products and services and the company’s focus and ambition in the specialty vehicle market. “We all know where the world is heading in terms of the switch to electric vehicles and we feel evTS has unique opportunities and competitive advantages in the commercial sector,” he added.

For more information, visit the company’s website at www.evTS.com.

NOTE TO INVESTORS: The latest news and updates relating to ev Transportation Services are available in the company’s newsroom at https://ibn.fm/EVTS

• Mohawk’s proprietary platform, AIMEE(R), can identify consumer-driven needs and help handle the entire go-to-market process, from determining demand and market opportunities to production under the Mohawk brand
• The company currently owns 12 brands in the e-commerce industry – 5 launched and 7 acquired
• 2020 saw $1 billion in fresh capital from firms looking to acquire Amazon marketplace seller assets
• Sellers on the Amazon marketplace sold a total of $200 billion worth of products in 2019

Yaniv Sarig, CEO of Mohawk Group Holdings (NASDAQ: MWK), didn’t start out as the entrepreneur he is today. Born in Israel and the son of an electronics engineer, Sarig spent part of his childhood living in Europe before moving back to Israel. Required to serve three years in the Israeli Army, he joined the IDF Special Forces. These three years are what he believes prepared him for entrepreneurship. In a podcast interview on Gamechangers LIVE, Sarig stated that it was the Special Forces that made him realize that he could do more (https://ibn.fm/IyZem). He said that what you think you can do is only a fraction of what you are capable of doing, and without setting the bar higher and higher, you will never know what you are capable of. Sarig also said that the largest obstacle entrepreneurs face today is the fear of failure. When there is fear of failure, there is loss of innovation. Nobody wants to share ideas for fear of them being turned down. As an entrepreneur, the only want to succeed and grow in the business is to embrace those failures and learn from them, he added. Sergio Tigera, the host of Gamechangers LIVE, asked Sarig when his game-changing moment was that made his entrepreneurial drive stronger. He told Tigera that he lost someone close to him, and when that happened, there was a realization that he owed it to them to “make the most of it.” Now, setting the bar higher, Sarig is the CEO of Mohawk. This tech-enabled consumer-centered products platform uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. Through its proprietary platform AIMEE(R) (AI Mohawk e-Commerce Engine), Mohawk can identify what consumers are searching for, determine what they want based on feedback about these products, create a targeted product for the consumers, and launch it under a Mohawk branded name. Mohawk is also noticing those businesses that already meet the consumer’s demand but cannot rise above their current positioning in the market.  In these instances, Mohawk will look at the product’s potential. If everything is in order, it will acquire those assets from the seller to market under the Mohawk name. When bringing a product to market, Mohawk’s goal is to go from targeting a market need to putting it in a consumer’s hand in as little time as possible. Most go-to-market processes are a process that takes 18 to 24 months. The Mohawk go-to-market business model reduces this down to just 6 to 8 months, Sarig explained. AIMEE(R) helps reduce a lot of the idea focus group research by leveraging real-time data-driven opportunities and trend tracking. Marketing time is also reduced due to the AIMEE(R) Trading Engine that provides data-driven automated marketing and product lifetime management. With the recent acquisition of Healing Solutions LLC through an asset-only agreement, Mohawk currently has 12 brands (5 launched, 7 acquired) in the e-commerce industry. All of these have been launched or acquired based on a consumer-centric need determined by the company. There are millions of brands available through Amazon that have acquisition potential. In 2020, there was nearly $1 billion in fresh capital committed to doing so by firms looking to acquire the brands. In 2019, sellers on the marketplace sold $200 billion worth of products, with statistics indicating that if the Amazon marketplace were a country, it would rank as the world’s 50th largest economy (https://ibn.fm/dl3IS). For more information, visit the company’s website at www.Mohawkgp.com. NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK

• Company has completed steps necessary to achieve, sustain competitive advantage in move towards remote-health solutions and trials
• RYAH technology optimizes patient feedback so medical trials, studies can move into remote solution zones
• Recently developed an integrated, customized mobile application to support a major clinical study in the United Kingdom
• RYAH created cloud of stored data to help with R&D of future medical treatments

RYAH Group, a leading digital health-care analytics and technology company, is on a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. The company believes that, when patients are given more control overdosing, doctors can offer personalized treatment plans based on collective information.

Accenture, a global professional service company, recently surveyed 128 life science industry leaders to better understand digital transformation in the lab. The survey results revealed the following three key steps, which life science companies must take in order to achieve and sustain a competitive advantage in a world with enormous amounts of data to sift through (https://ibn.fm/ZQ3uz):

• Lay the groundwork with automation, connecting all instruments and digital data capturing
• Move toward a cloud-based, multivendor platform with enhanced security, data access, instrument integration and more with analytics powered insights to enhance workflow and compliance
• Create and power an end-to-end data supply chain, deeper adoption of AI, with whole lab automation and implementation

RYAH is meeting each of these steps head-on by creating useful technology that collects, analyzes and leverages objective data on therapeutic plant usage. Patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time. The patient controls the process, and the instruments that collect digital data remain anonymous.

When patient feedback is optimized, medical trials and studies can move into remote solution zones. RYAH has recently developed a custom solution where a patient session temperature and dosing is set and locked by the clinical partner, suitable for both medium- and large-scale studies.

In 2013 the FDA suggested a shift to remote monitoring (https://ibn.fm/3pr60), but the industry has been slow to adopt the necessary technology — until COVID-19 made it nearly impossible to conduct traditional monitoring. In today’s pandemic setting, more clinical trials are needed that connect patients and researchers without the need for in-person monitoring or unnecessary risk to exposure.

Communication between the monitor and the patient is essential. Notifications, in-app messaging and push notifications help create personalized plans for patients, tailored to their unique conditions and tolerance of the treatment.

RYAH is focused on expanding the understanding of proprietary technology that supports a data-driven approach to positively impact patients’ future treatment for various medical conditions. By coupling a anonymous database with AI, the company has created a cloud of stored data to help with the R&D of future medical treatments. RYAH is actively making digital transformation in the lab a reality, paving the way forward for a medical future with remote solutions.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• Both heart disease, poor metabolic health increase complications of COVID-19, according to health professionals
• HYB Holding Corp. offers cloud-based software that transforms analog ultrasound 2D images into a digital 3D HD formats that quantify diagnostic capabilities
• Software can be used to enhance ultrasound images of vital organs, tendons, skin, nerves for use across multiple healthcare markets
• Provisional patent filed with U.S. Patent and Trademark Office

Epidemiologists observed that people with cardiovascular disease were more than twice as likely to contract severe forms of COVID-19 (https://ibn.fm/wG2j4). HYB Holding (OTC: HYBG), through its Mediscan Inc. subsidiary, offers imaging solutions to ultrasound professionals through cloud-based software that reconstructs analog 2D grayscale visual images into digital 3D high-definition quantifiable formats that can address the critical need to monitor COVID-19 patients for cardiac damage.

While death rates from COVID-19 have dropped significantly in the last six months, cardiovascular disease continues to remain a major predictor of poor outcome. HYBG’s Mediscan software application helps ultrasound technicians derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma while facilitating support for treatment options. The software additionally enables health professionals to monitor the patient’s ongoing progress or regress while documenting compliance with required protocols and procedures.

The company’s software specifically transforms ultrasound analog 2D grayscale images into digital 3D HD format that helps technicians derive data-driven insights into the condition of a patient.  Along with vital organs like the heart, the technique can generate 3D medical images of other parts of the body such as the lungs, tendons, skin and nerves for analysis by emergency medical services (EMS) and other health professionals such as primary care physicians, specialists, technical support staff and sports trainers.

The software is cloud-based and easy to use anywhere there is an internet connection, providing point-of-service medical professionals comparable image quality of CT or X-ray but without the radiation risk and at a far lower cost. Besides upgrading services for healthcare professionals, Mediscan software provides a convenient and comfortable medical experience for patients.

The company plans to make the software available as medical software-as-a-service (SaaS), a widely-used model in the health care industry for clinical information systems, supply chain management, revenue cycle management and billing. Along with operational cost-savings, the SaaS model eliminates the need for external hardware and software configurations as well as technical onsite maintenance. HYBG has a patent application filed with the United States Patent and Trademark Office through its Mediscan subsidiary for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

Flexible and easy-to-use, portable ultrasounds equipped with Mediscan’s application empower health care providers to evaluate, triage and diagnose the effects of heart disease on COVID-19 patients. The increasing demand for early diagnosis and the widening scope of clinical applications create a promising opportunity for Mediscan to fulfill its mission of developing and distributing medical imaging solutions to both long-term care facilities and acute and emergency medical services.

For more information, visit the company’s website at www.MyMediScan.com.

NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

• CBD-based products have become increasingly popular among professional athletes, primarily due to pain-relieving, anti-inflammatory qualities
• CannAssist International’s Xceptor Labs is an active player within the CBD-based product sector through the development of its proprietary CiBiDinol technology
• CiBiDinol’s technology, using a water-soluble carrier, developed an encapsulation process to deliver unchanged CBD molecule through cell’s watery matrix
• Xceptor Labs has seen rapid uptake in products’ popularity, with ten products now available for sale online

When three-time National Football League tight end Rob Gronkowski first announced his retirement from professional football, he attributed part of the decision to the heavy toll that injuries and nine subsequent surgeries had had on his ravaged body. However, the use of cannabidiol (“CBD”)-based topical pain relief products and the significant benefit provided by these played a large part in influencing the Super Bowl-winning athlete to return to the professional sports arena. CannAssist International (OTCQB: CNSC), a biotechnological pharmaceutical company and owner of Xceptor Labs, has sought to capitalize on the growing prominence CBD-based products within professional sports through its innovative technology and proprietary product portfolio. The chronic use of over-the-counter pain relievers (i.e., nonsteroidal anti-inflammatory drugs or NSAIDs) and opioids are widely documented as posing more significant health risks previously known, with opioid addictions leading to the deaths of thousands of Americans annually. In such a landscape, professional athletes have been eager to learn about the pain relief and inflammation-reducing qualities found in CBD products while forgoing the risks commonly associated with NSAIDs or opioids. The interest in CBD for pain alleviation has only gained further momentum following the World Anti-Doping Agency (“WADA”) and the US Anti-Doping Agency (“USADA”) ‘s joint decision to remove CBD from their list of prohibited substances – in or out of competition (https://ibn.fm/8aXyt). In a sector that has seen its ranks rapidly swell given an influx of new entrants, CannAssist’s wholly-owned Xceptor Labs has sought to differentiate itself through the use and development CiBiDinol technology. CiBiDinol’s technological make-up is a proprietary process specifically designed to address a number of the shortcomings currently afflicting oil-soluble CBD molecules. These advantages in delivery, bioavailability and short shelf-life (https://ibn.fm/uigze) have been verified with third-party testing habitually demonstrating a 300% increase in gut absorption rate and a 400% increase in skin penetration for CiBiDinol relative to regular oil-based CBD (https://ibn.fm/n0x1m). Perhaps more critically, the product’s effective absorption has also allowed for lower dosage requirements, thereby significantly lowering the amount of CBD needed to achieve its targeted endpoints. In September 2020, Xceptol brand pain creams containing CiBiDinol were released; each cream carries FDA-registered ingredients, designed to provide localized fast-acting relief for sore, aching muscles and joints. In December 2020, the company added seven more SKU’s that include capsules and drops; Xceptol’s full range of consumer products is now available on www.xceptol.com and www.RangeMe.com, a site dedicated to vetting brands for large retailers. “This is exciting news for us on many fronts; a process estimated to take weeks we accomplished in a few days – a testament, I feel, to the quality of the Xceptol brand,” noted CannAssist CEO Mark Palumbo regarding the news. “Also gratifying is being included on the RangeMe website, a significant portal for major retailers to find products for their customers.” The global CBD industry is set to rise from a market value of $4.6 billion in 2018 to an estimated $23.6 billion by 2025 (https://ibn.fm/SI4g6), CannAssist International seems advantageously positioned to benefit from the ongoing upswell in interest in CBD. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Golden Leaf Holdings Ltd. is licensed in Oregon and Nevada, with partnerships in manufacturing and distribution in California
• The Chalice Brands offer full lines of cannabis products grown organically and by local growers
• The company offers production, processing, wholesale distribution and retail operations within the cannabis industry
• Golden Leaf Holdings reported sales growth during the pandemic, recording revenue of $6.2 million in Q3 2020, an increase of 42% from Q3 2019. At the end of the third quarter, the company had exceeded total fiscal 2019 revenues
• The cannabis market is forecast to achieve a CAGR of 18.1%, climbing to a value of $73.6 billion by 2027

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF) is a premier consumer-driven cannabis company powered by the Chalice retail and consumer brands. GLH takes a diversified approach to growth through innovation, strategic partnerships and retail expansion, as well as a brand portfolio focusing on health and wellness. The company features best in class retail cannabis experiences backed by cultivation, processing and developing wholesale distribution. With over 160 employees, GLH is one of the largest cannabis operators in Oregon. The company holds licensing in Oregon, as well as partnerships for manufacturing and distribution in California. Its current product portfolio includes recognizable brands such as Chalice(TM), Elysium Fields(TM), GOLDEN(TM), Jackpot(TM) and RXO(TM). Brands Golden Leaf Holdings offers an innovative product line that addresses current market needs and looks forward to meet emerging trends. The company’s goal is to offer something for everyone through the wholesale and retail marketplaces. Its current product offerings include: Chalice(TM) The Chalice Farms(TM) brand is focused on how cannabis enhances lives and ignites purpose. By offering the highest quality of cannabis in an array of flower, extracts, oils, edibles and full-body care products, the brand provides full efficacy in both the retail and wholesale markets. The Chalice Farms team has over 100 years of combined cannabis experience and continues to be an industry leader for both medical and recreational cannabis use – providing state-of-the-art farming practices, excellent retail and complete product innovation. Elysium Fields(TM) Elysium Fields(TM) is a “soil-to-oil” craft cannabis brand intended for cannabis connoisseurs who want the highest quality THC and boldest terpene flavors. Made from small-batch live resin, Elysium Fields creates an experience described as a remarkable entourage effect. The C-Cell cartridge has a 30% strain specific HTE with a 70% high THC distillate. The resin is created from a sustainable, organic garden flower that is flash-frozen upon harvest to preserve the terpenes for a heavenly experience. RXO(TM) RXO(TM) features Chalice Farms’ purest and most versatile Rick Simpson Oil products. RXO was developed by the Steele brothers in collaboration with medical professionals and is a potent, strain-specific Ethanol Hash Oil (“EHO”) purified through a proprietary process. Through this process, various consumption methods can be accommodated, including edible, topical, sublingual and smoking (shatter and vape). GOLDEN(TM) GOLDEN(TM) offers a wide variety of craft cannabis products for a diverse population of cannabis users. Sourced from the finest raw materials from local growers, GOLDEN products are high-quality and innovative. Premium cannabis distillate vaporizer cartridges and fruit chew edibles made from organic ingredients are made using the most flavorful terpenes for enhanced health, wellness and enjoyment. Products are distributed online and through Chalice Farms or other dispensary partners. Jackpot(TM) Jackpot(TM) products offer a powerful combination of flavor and potency. With 70% THC content in each cartridge, Jackpot adds full-spectrum cannabinoids and flavorful infused terpenes in short-run limited strains for on-the-go fun seekers. The quality hardware of the cartridges makes them easily recyclable and guarantees to produce a large volume draw each time. Cannabis Market Outlook In 2020, the legal cannabis market was valued at approximately $23 billion, and it is expected to top $73.6 billion in revenue by 2027, growing at a CAGR of 18.1% during the forecast period (https://ibn.fm/LdkhG). One of the biggest factors driving the cannabis market’s growth is legalization around the world. As cannabis sales generally increased during the pandemic, Golden Leaf Holdings achieved record financials for Q3 2020, reporting quarterly revenue of $6.2 million, a year-over-year increase of 42%. For the first time in its history, the company also reported positive cash flow in excess of $417,000 (https://ibn.fm/LY1b2). Golden Leaf Holdings is uniquely positioned to capitalize on the growth of both the medicinal and recreational marijuana market segments through a rich product offering that successfully addresses current consumer needs. Management Team Jeff Yapp is the CEO and President of Golden Leaf Holdings Ltd. He has created a culture at GLH that operates under his mantra of ‘Crawl, Walk, Run’. He is an accomplished entrepreneur and corporate executive who has built a successful career through his ability to recognize opportunity, even when it isn’t obvious. Mr. Yapp has an extensive background in retail, marketing and entertainment. In the past, he has been committed to bringing innovation to Fortune 25 companies such as Microsoft, Kraft Foods, PepsiCo and more. As a strategic partner for Microsoft, he is an integral driver of growth for online and retail operations. He graduated with honors from the University of Michigan, majoring in Business Administration. He also graduated with honors from JL Kellogg School of Management at Northwestern University. John Varghese is the Executive Chair of Golden Leaf Holdings and is responsible for all capital markets initiatives at GLH. His background is in mergers and acquisitions, investing, operations and capital markets, with professional experience that ranges from private equity, venture capital and investment banking to senior management positions and director roles in both private and public companies. He has served on over 20 boards, acting as the chairman of six of them. Andrew Marchington is the company’s CFO. His public accounting career experience includes time with start-up, high-growth and enterprise-level organizations, including five years of prior cannabis industry experience. He has a rich understanding of the priorities and best practices within accounting, finance and management. Mr. Marchington’s past experience includes time with companies like Deloitte, Moss Adams, Cambia Health Solutions and C21 Investments. John Ford, Golden Leaf Holdings’ Chief Revenue Officer and VP of Retail, is a seasoned and dynamic retail leader with extensive experience in the retail industry who has led the launch of major retail brands such as Apple and Microsoft in China and Australia. His goal is to help retailers transition their businesses to modern experiential locations where customers can engage with products and brands in new ways. At Apple, Mr. Ford was the only field expat sent to launch Apple Retail in China. He set several records for Apple while in China, not just in sales but also in inventory management and employee turnover. Mr. Ford left Apple to lead Microsoft’s international retail expansion, where he also managed its e-commerce presence. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF